Overview

A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS)

Status:
Completed
Trial end date:
2021-05-19
Target enrollment:
Participant gender:
Summary
This study is a multi center, open-label, study of ANX005 in combination with IVIg in subjects diagnosed with GBS.
Phase:
Phase 1
Details
Lead Sponsor:
Annexon, Inc.
Collaborators:
International Centre for Diarrhoeal Disease Research, Bangladesh
ResearchPoint Global
Treatments:
Antibodies
gamma-Globulins
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin